{"id":"https://openalex.org/W4310124896","doi":"https://doi.org/10.1182/blood-2022-168003","title":"Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease","display_name":"Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310124896","doi":"https://doi.org/10.1182/blood-2022-168003"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-168003","doi":"https://doi.org/10.1182/blood-2022-168003","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-168003","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069318096","display_name":"Christine E. Ryan","orcid":"https://orcid.org/0000-0003-2588-1943","observed_orcids":["https://orcid.org/0000-0003-2588-1943"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine E. Ryan","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017380326","display_name":"Benjamin L. Lampson","orcid":"https://orcid.org/0000-0002-6033-3363","observed_orcids":["https://orcid.org/0000-0002-6033-3363"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin L. Lampson","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010499534","display_name":"Svitlana Tyekucheva","orcid":"https://orcid.org/0000-0002-3119-6507","observed_orcids":["https://orcid.org/0000-0002-3119-6507"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svitlana Tyekucheva","raw_affiliation_strings":["2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018834596","display_name":"Liam R. Hackett","orcid":"https://orcid.org/0000-0002-3330-2369","observed_orcids":["https://orcid.org/0000-0002-3330-2369"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liam R. Hackett","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008387891","display_name":"Yue Ren","orcid":"https://orcid.org/0009-0003-4777-3342","observed_orcids":["https://orcid.org/0009-0003-4777-3342"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yue Ren","raw_affiliation_strings":["2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047529156","display_name":"Samantha J. Shupe","orcid":"https://orcid.org/0000-0002-0138-9420","observed_orcids":["https://orcid.org/0000-0002-0138-9420"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samantha J. Shupe","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009506175","display_name":"Stacey M. Fernandes","orcid":"https://orcid.org/0000-0002-5061-5199","observed_orcids":["https://orcid.org/0000-0002-5061-5199"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacey M. Fernandes","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088077600","display_name":"Jennifer Leigh Crombie","orcid":"https://orcid.org/0000-0003-3445-5129","observed_orcids":["https://orcid.org/0000-0003-3445-5129"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer L. Crombie","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110647265","display_name":"Samuel Y. Ng","orcid":"https://orcid.org/0000-0003-1140-0627","observed_orcids":["https://orcid.org/0000-0003-1140-0627"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samuel Ng","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017446407","display_name":"Austin Injae Kim","orcid":"https://orcid.org/0000-0003-1039-0658","observed_orcids":["https://orcid.org/0000-0003-1039-0658","https://orcid.org/0000-0002-9675-9374"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Austin I. Kim","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055037645","display_name":"Inhye E. Ahn","orcid":"https://orcid.org/0000-0003-3717-287X","observed_orcids":["https://orcid.org/0000-0003-3717-287X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Inhye E. Ahn","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Matthew J Weinstock","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew J Weinstock","raw_affiliation_strings":["3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069822416","display_name":"Samantha Pazienza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samantha Pazienza","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021158149","display_name":"Josie S. Montegaard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josie S. Montegaard","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012072790","display_name":"Victoria Patterson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victoria Patterson","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037526878","display_name":"Caron Alyce Jacobson","orcid":"https://orcid.org/0000-0002-0180-0654","observed_orcids":["https://orcid.org/0000-0002-0180-0654"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caron A. Jacobson","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085801543","display_name":"Ann Steward LaCasce","orcid":"https://orcid.org/0000-0001-7349-0176","observed_orcids":["https://orcid.org/0000-0001-7349-0176"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann S. LaCasce","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101930428","display_name":"David Christopher Fisher","orcid":"https://orcid.org/0000-0001-6915-8584","observed_orcids":["https://orcid.org/0000-0001-6915-8584"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Fisher","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016770040","display_name":"Jon E. Arnason","orcid":"https://orcid.org/0000-0001-9038-7277","observed_orcids":["https://orcid.org/0000-0001-9038-7277"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon E. Arnason","raw_affiliation_strings":["4Hematologic Malignancy and Bone Marrow Transplantation Program, Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Hematologic Malignancy and Bone Marrow Transplantation Program, Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063573668","display_name":"Steve Lo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802195419","display_name":"Stamford Hospital","ror":"https://ror.org/05jr4qt09","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802195419"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steve Lo","raw_affiliation_strings":["5Stamford Hospital, Stamford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Stamford Hospital, Stamford, CT","institution_ids":["https://openalex.org/I2802195419"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058210944","display_name":"Adam J. Olszewski","orcid":"https://orcid.org/0000-0002-6472-6658","observed_orcids":["https://orcid.org/0000-0002-6472-6658"]},"institutions":[{"id":"https://openalex.org/I27804330","display_name":"Brown University","ror":"https://ror.org/05gq02987","country_code":"US","type":"education","lineage":["https://openalex.org/I27804330"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam Olszewski","raw_affiliation_strings":["6Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI","institution_ids":["https://openalex.org/I27804330"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":4.0876,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.95382027,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":94,"max":99},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"837","last_page":"838"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.777999997138977},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9980000257492065},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9589999914169312},{"id":"https://openalex.org/keywords/high-risk-cll","display_name":"high-risk CLL","score":0.765999972820282},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":0.7710000276565552},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.6800000071525574},{"id":"https://openalex.org/keywords/bcl-2-dependence","display_name":"BCL-2 dependence","score":0.7900000214576721},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8149999976158142},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.5680000185966492},{"id":"https://openalex.org/keywords/hepatic-veno-occlusive-disease","display_name":"veno-occlusive disease","score":0.578000009059906},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.5059999823570251},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.41999998688697815},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.5740000009536743}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.7530136108398438},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7072654962539673},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.6463518738746643},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.6143571734428406},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5782735347747803},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5580278038978577},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.517751157283783},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.4546036124229431},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4369962513446808},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42239993810653687},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.19491317868232727},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1932215690612793},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.17983683943748474},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-168003","doi":"https://doi.org/10.1182/blood-2022-168003","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-168003","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3095558229","https://openalex.org/W2987080466","https://openalex.org/W4417006981","https://openalex.org/W4405042808","https://openalex.org/W3213981466","https://openalex.org/W4405034648","https://openalex.org/W3097014789","https://openalex.org/W4405133743","https://openalex.org/W4405049028","https://openalex.org/W4405035249"],"abstract_inverted_index":{"Background":[0],"While":[1],"venetoclax":[2],"(V)":[3],"plus":[4,25],"obinutuzumab":[5],"(O)":[6],"is":[7,30,201,254,367,427,480,652,690],"a":[8,43,78,120,385,669,691,697,727],"highly":[9,692],"effective":[10],"frontline":[11,698],"CLL":[12,101,130,501,699],"regimen,":[13],"outcomes":[14],"remain":[15,556],"suboptimal":[16],"for":[17,139,477,702],"high-risk":[18,85,703],"patients":[19],"(pts).":[20],"The":[21,364],"efficacy":[22,226],"of":[23,146,184,194,276,290,314,387,404,462,486,552,624,638,707,715,730,736,748],"ibrutinib":[24],"VO":[26],"in":[27,110,306,452,464,672,696,723],"such":[28],"pts":[29,99,127,205,295,350,389,405,417,463,479,489,514,554,630,634,659,678,709,725],"encouraging,":[31],"but":[32],"cardiac":[33,737],"and":[34,56,74,152,186,243,272,433,498,510,526,538,618,654,738],"infectious":[35,739],"toxicities":[36,231],"(tox)":[37,232],"are":[38,718],"common.":[39],"We":[40,58],"hypothesized":[41],"that":[42,658],"time-limited":[44,751],"triplet":[45,695],"with":[46,81,100,102,128,165,216,279,311,390,418,508,519,528,705,720],"the":[47,93,191,217,348,359,415,424,487,749],"more":[48],"selective":[49],"BTKi":[50],"acalabrutinib":[51],"(A)":[52],"would":[53],"be":[54],"active":[55],"well-tolerated.":[57],"previously":[59,125,258],"published":[60],"results":[61,408],"on":[62,77,92,155,163,265,457,524,663],"an":[63,285],"initial":[64,94,655],"cohort":[65,80,302],"unrestricted":[66],"by":[67,119,143,227,233,237,284,376,396,440],"genetic":[68,104],"risk":[69,105],"(Davids":[70],"et":[71,262],"al.,":[72,263],"2021),":[73],"now":[75],"report":[76],"new":[79],"enrollment":[82],"restricted":[83,123],"to":[84,124,169,219,247,352,410,548,664],"pts,":[86,322,561],"as":[87,89,257,682],"well":[88],"longer":[90],"follow-up":[91,313,729],"cohort.":[95],"Methods":[96],"Treatment":[97],"(tx)-na\u00efve":[98],"any":[103],"profile":[106],"were":[107,296,394,449,741],"initially":[108],"enrolled":[109,297],"this":[111,307],"investigator-sponsored,":[112],"phase":[113],"2":[114,144,303,485,527],"study":[115,309,536,543],"(cohort":[116,131,298],"1),":[117],"followed":[118,142],"multi-center":[121],"expansion":[122],"untreated":[126],"TP53-aberrant":[129,335,419,708],"2).":[132],"A":[133,641],"starts":[134,154],"at":[135,149,157,203,223,354,398,422,675,726],"100":[136],"mg":[137,162,171],"BID":[138],"28":[140],"days,":[141],"cycles":[145,183],"AO":[147],"(O":[148],"standard":[150],"dosing),":[151],"V":[153,176,644],"C4D1":[156,676],"20":[158],"mg,":[159],"then":[160],"50":[161],"C4D2,":[164],"weekly":[166],"ramp-up":[167],"thereafter":[168],"400":[170],"QD":[172],"(total":[173],"4":[174],"week":[175],"ramp-up).":[177],"AVO":[178,689,752],"continues":[179,188],"C5-7":[180],"(6":[181],"total":[182],"O),":[185],"AV":[187,213,509],"C8-15.":[189],"If":[190],"primary":[192,360],"endpoint":[193,361],"undetectable":[195],"bone":[196],"marrow":[197],"MRD":[198,236,375,439,455,495],"(BM-uMRD)":[199],"CR":[200,466,547,666],"reached":[202],"C16D1,":[204,355,374,423],"can":[206],"discontinue":[207,220],"therapy":[208],"(tx);":[209],"all":[210,320,504,553,559,590,594,616,724],"others":[211],"continue":[212],"through":[214],"C24,":[215],"option":[218],"if":[221],"BM-uMRD":[222,362,381,437,445,465,711],"C25D1.":[224],"Assessments:":[225],"2018":[228],"iwCLL":[229],"criteria,":[230],"CTCAE":[234],"v5,":[235],"central":[238],"8-color":[239],"flow":[240],"(10-4":[241],"sensitivity)":[242],"NGS":[244,397],"clonoSEQ":[245],"(up":[246],"10-6":[248],"sensitivity,":[249],"Adaptive).":[250],"BH3":[251,650],"profiling":[252,651],"work":[253],"ongoing,":[255,653],"performed":[256],"described":[259],"(Ryan":[260],"J":[261],"2016)":[264],"peripheral":[266],"blood":[267],"(PB)":[268],"samples":[269],"after":[270,470,521,534,712],"1":[271,299,499,518,622],"3":[273,505,513,732],"cycles.":[274],"Association":[275],"BCL-2":[277,673],"dependence":[278,674],"clinical":[280],"response":[281,453,684],"was":[282],"compared":[283],"unpaired":[286],"t-test.":[287],"Results":[288],"As":[289],"13":[291,532],"July":[292],"2022,":[293],"68":[294,321,560],"all-comers:":[300],"n=37,":[301],"TP53-aberrant:":[304],"n=31)":[305],"ongoing":[308],"(NCT03580928),":[310],"median":[312,323,473,728],"35":[315],"mos":[316,482,523,533,541,714],"(range":[317,327,483],"2-45).":[318],"In":[319,384,414,558],"age":[324],"63":[325],"yrs":[326],"36-80);":[328],"25%":[329],"\u226570":[330],"yrs;":[331],"66%":[332],"male;":[333],"60%":[334],"(del(17p)":[336],"or":[337,454,646],"mut);":[338],"24%":[339],"complex":[340],"karyotype":[341],"(\u22653":[342],"abnormalities);":[343],"74%":[344],"unmutated":[345],"IGHV.":[346],"Of":[347],"56":[349],"evaluable":[351,421],"date":[353],"43%":[356],"(24/56)":[357],"achieved":[358,436,511,546,680],"CR.":[363],"best":[365,425,683],"ORR":[366,426],"98%":[368],"(48%":[369],"CR,":[370,430,438],"50%":[371],"PR).":[372],"At":[373],"flow:":[377,441],"86%":[378,380,442],"PB-uMRD,":[379,443],"(Fig":[382,446],"1A).":[383,447],"subset":[386],"49":[388],"available":[391],"samples,":[392],"59%":[393,403],"PB-uMRD":[395],"10-5":[399],"sensitivity":[400],"(at":[401],"10-6,":[402],"had":[406,494,500,631],"indeterminate":[407],"due":[409],"low":[411],"cell":[412],"counts).":[413],"29":[416],"disease":[420,502],"100%":[428],"(52%":[429],"48%":[431],"PR),":[432],"45%":[434],"(13/29)":[435],"83%":[444,706],"There":[448],"no":[450],"differences":[451],"based":[456],"IGHV":[458],"status.":[459],"79%":[460],"(19/24)":[461],"electively":[467],"discontinued":[468,491],"tx":[469,476,492,507,537],"15":[471,522,713],"cycles;":[472],"time":[474],"off":[475],"these":[478],"22.9":[481],"1-30).":[484],"19":[488],"who":[490,660,679],"have":[493,668],"only":[496,640,643],"recurrence,":[497],"progression;":[503],"restarted":[506],"PR.":[512],"developed":[515],"Richter's":[516],"syndrome:":[517],"DLBCL":[520],"study,":[525],"Hodgkin":[529],"transformation":[530],"(one":[531],"completing":[535],"one":[539],"12":[540],"into":[542],"tx;":[544],"both":[545,647],"Hodgkin-directed":[549],"tx).":[550],"93%":[551,721],"(63/68)":[555],"progression-free.":[557],"all-grade":[562],"heme":[563],"tox":[564,740],"included:":[565],"neutropenia":[566],"(75%;":[567],"37%":[568],"Gr3/4),":[569,573],"thrombocytopenia":[570],"(73%;":[571],"28%":[572],"anemia":[574],"(49%,":[575,593],"3%":[576],"Gr3).":[577],"Non-heme":[578],"tox:":[579],"headache":[580],"(78%,":[581],"1%":[582,586,612],"Gr3),":[583,587,599,604,608,613],"fatigue":[584],"(76%,":[585],"bruising":[588],"(66%,":[589],"Gr1/2),":[591,595],"nausea":[592],"diarrhea":[596],"(40%,":[597],"4%":[598,603],"infusion-related":[600],"reaction":[601],"(30%,":[602],"hypertension":[605],"(27%;":[606],"9%":[607],"increased":[609],"ALT":[610],"(27%,":[611],"arthralgia":[614],"(25%,":[615],"Gr1),":[617],"infection":[619],"(6%":[620],"Gr3;":[621],"case":[623],"Gr5":[625],"COVID-19":[626],"pneumonia).":[627],"2.9%":[628],"(2/68)":[629],"afib.":[632],"14":[633],"(21%)":[635],"required":[636],"dose-reduction":[637],"either":[639],"(4%),":[642],"(9%),":[645],"drugs":[648],"(7%).":[649],"data":[656,744],"suggest":[657],"later":[661],"went":[662],"achieve":[665],"may":[667],"greater":[670],"increase":[671],"than":[677],"PR":[681],"(p=0.05,":[685],"Fig":[686],"1B).":[687],"Conclusion":[688],"active,":[693],"well-tolerated":[694],"population":[700],"enriched":[701],"disease,":[704],"achieving":[710],"tx.":[716],"Responses":[717],"durable,":[719],"PFS":[722],"nearly":[731],"yrs.":[733],"Low":[734],"rates":[735],"observed.":[742],"Our":[743],"support":[745],"continued":[746],"investigation":[747],"MRD-guided,":[750],"triplet.":[753],"Figure":[754],"1View":[755,758],"largeDownload":[756,759],"PPTFigure":[757],"PPT":[760],"Close":[761],"modal":[762]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":9}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}